Meridian Bioscience Reports Third Quarter 2019 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Meridian Bioscience (VIVO) Tops Q3 EPS by 7c, Revenues Miss; Offers FY19 EPS Guidance
July 30, 2019 7:35 AM EDTMeridian Bioscience (NASDAQ: VIVO) reported Q3 EPS of $0.16, $0.07 better than the analyst estimate of $0.09. Revenue for the quarter came in at $48.4 million versus the consensus estimate of $49.81 million.
Third Quarter 2019 Highlights (Comparison to Third Quarter Fiscal 2018):
Consolidated revenue decreased 6% to $48.4 million (5% decrease in constant-currency)Diagnostics segment revenues decreased 9% to $33.1 million (8% decrease in constant-currency)Life Science segment revenues were flat at $15.3 million (1% growth in constant-currency)Reported GAAP operating income of $6.5 million (including $2.5 million of costs associated with acquisition activities, restructuring activities and selected legal proceedings), as compared to $8.7 million last... More